146 related articles for article (PubMed ID: 35581455)
21. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
[TBL] [Abstract][Full Text] [Related]
22. Reviewing state-mandated training requirements for naloxone-dispensing pharmacists.
Roberts AW; Carpenter DM; Smith A; Look KA
Res Social Adm Pharm; 2019 Feb; 15(2):222-225. PubMed ID: 29650444
[TBL] [Abstract][Full Text] [Related]
23. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
[TBL] [Abstract][Full Text] [Related]
24. State laws that authorize pharmacists to prescribe naloxone are associated with increased naloxone dispensing in retail pharmacies.
Xu J; Mukherjee S
Drug Alcohol Depend; 2021 Oct; 227():109012. PubMed ID: 34482035
[TBL] [Abstract][Full Text] [Related]
25. Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy.
Hines KL; Garofoli GK; Garofoli MP; Elswick BM; Winstanley EL
J Am Pharm Assoc (2003); 2020; 60(6):e205-e214. PubMed ID: 32800678
[TBL] [Abstract][Full Text] [Related]
26. Pharmacists' naloxone services beyond community pharmacy settings: A systematic review.
Rawal S; Osae SP; Cobran EK; Albert A; Young HN
Res Social Adm Pharm; 2023 Feb; 19(2):243-265. PubMed ID: 36156267
[TBL] [Abstract][Full Text] [Related]
27. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
[TBL] [Abstract][Full Text] [Related]
28. The pharmacist's role in overdose: Using mapping technologies to analyze naloxone and pharmacy distribution.
Burrell A; Ethun L; Fawcett JA; Rickard-Aasen S; Williams K; Kearney SM; Pringle JL
J Am Pharm Assoc (2003); 2017; 57(2S):S73-S77.e1. PubMed ID: 28109629
[TBL] [Abstract][Full Text] [Related]
29. Pharmacy-based statewide naloxone distribution: A novel "top-down, bottom-up" approach.
Morton KJ; Harrand B; Floyd CC; Schaefer C; Acosta J; Logan BC; Clark K
J Am Pharm Assoc (2003); 2017; 57(2S):S99-S106.e5. PubMed ID: 28292508
[TBL] [Abstract][Full Text] [Related]
30. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
[TBL] [Abstract][Full Text] [Related]
31. A standardized team-based approach for identifying naloxone-eligible patients in a grocery store pharmacy.
Sexton SM; Armstrong A; Gatton O; Rhodes LA; Marciniak MW
J Am Pharm Assoc (2003); 2019; 59(4S):S95-S100. PubMed ID: 31231001
[TBL] [Abstract][Full Text] [Related]
32. Factors associated with naloxone availability and dispensing through Michigan's pharmacy standing order.
Dahlem CH; Myers M; Goldstick J; Stevenson JG; Gray G; Rockhill S; Dora-Laskey A; Kellenberg J; Brummett CM; Kocher KE
Am J Drug Alcohol Abuse; 2022 Jul; 48(4):454-463. PubMed ID: 35405078
[No Abstract] [Full Text] [Related]
33. The changing landscape of naloxone availability in the United States, 2011 - 2017.
Freeman PR; Hankosky ER; Lofwall MR; Talbert JC
Drug Alcohol Depend; 2018 Oct; 191():361-364. PubMed ID: 30195192
[TBL] [Abstract][Full Text] [Related]
34. Acceptability of Naloxone Dispensing Among Pharmacists.
Do V; Behar E; Turner C; Geier M; Coffin P
J Pharm Pract; 2020 Jun; 33(3):247-254. PubMed ID: 30180774
[TBL] [Abstract][Full Text] [Related]
35. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
[TBL] [Abstract][Full Text] [Related]
36. Concurrent Naloxone Dispensing Among Individuals with High-Risk Opioid Prescriptions, USA, 2015-2019.
Guy GP; Strahan AE; Haegerich T; Losby JL; Ragan K; Evans ME; Jones CM
J Gen Intern Med; 2021 Oct; 36(10):3254-3256. PubMed ID: 33751410
[No Abstract] [Full Text] [Related]
37. State legal innovations to encourage naloxone dispensing.
Davis C; Carr D
J Am Pharm Assoc (2003); 2017; 57(2S):S180-S184. PubMed ID: 28073688
[TBL] [Abstract][Full Text] [Related]
38. Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial.
Pollini RA; Ozga JE; Joyce R; Xuan Z; Walley AY
Drug Alcohol Depend; 2022 Feb; 231():109259. PubMed ID: 34998246
[TBL] [Abstract][Full Text] [Related]
39. Piloting an opioid callback program in community pharmacies.
Hernandez SE; Gilson AM; Gassman M; Ford JH
J Am Pharm Assoc (2003); 2023; 63(6):1796-1802. PubMed ID: 37574197
[TBL] [Abstract][Full Text] [Related]
40. Impact of a publicly funded pharmacy-dispensed naloxone program on fatal opioid overdose rates: A population-based study.
Antoniou T; Men S; Tadrous M; Leece P; Munro C; Gomes T
Drug Alcohol Depend; 2022 Jul; 236():109473. PubMed ID: 35523113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]